Compass TherapeuticsCMPX +0.86%23 Market Cap is $421.41 Mil as of Jul. 09, 2026. GuruFocus rates CMPX with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 1,420 Biotechnology companies, Compass Therapeutics ranks better than 68.24% on this metric.
Compass Therapeutics's quarterly market cap
increased
from Sep. 2025 ($621.50 Mil) to Dec. 2025 ($957.60 Mil) but then
declined
from Dec. 2025 ($957.60 Mil) to Mar. 2026 ($952.67 Mil).
Compass Therapeutics's annual market cap
increased
from Dec. 2023 ($199.16 Mil) to Dec. 2024 ($199.84 Mil) and
increased
from Dec. 2024 ($199.84 Mil) to Dec. 2025 ($957.60 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Compass Therapeutics's Enterprise Value for Today is $236.51 Mil.
Compass Therapeutics (NAS:CMPX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Compass Therapeutics Market Cap Related Terms
Compass Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Compass Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Compass Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Compass Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Compass Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Compass Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compass Therapeutics (CMPX) has a Market Cap of $421.41 Mil as of Jul. 09, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Compass Therapeutics and its competitors. According to the industry distribution chart, Compass Therapeutics ranks #451 out of 1420 companies in the Biotechnology industry, placing it in the top 31.8%.
Is Compass Therapeutics' Market Cap too high?
Compass Therapeutics' current Market Cap is $421.41 Mil. The Biotechnology industry median Market Cap is 121.52. Compass Therapeutics' value of $421.41 Mil is 246.8% above this industry median. Based on the distribution chart, Compass Therapeutics ranks #451 out of 1420 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Compass Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Compass Therapeutics' Market Cap compare to XFOR and LRMR?
According to the Biotechnology industry distribution chart, Compass Therapeutics ranks #451 out of 1420 companies for Market Cap. This puts Compass Therapeutics in the upper half of its industry. The industry median Market Cap is 121.52. Compass Therapeutics' value of $421.41 Mil is 246.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.52, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compass Therapeutics's current Market Cap of $421.41 Mil is 246.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Compass Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 121.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compass Therapeutics's current Market Cap is $421.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Therapeutics stock overvalued right now?
Compass Therapeutics (CMPX) has a current Market Cap of $421.41 Mil. The current Market Cap is $421.41 Mil and 246.8% above the Biotechnology industry median of 121.52. Compass Therapeutics' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Compass Therapeutics (CMPX), the current Market Cap is $421.41 Mil as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
23GF Score
Get the complete analysis for CMPX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMPX has been successfully added to your 
